A LinkedIn post from Dash Bio highlights commentary from a panel at the SLAS (Society for Laboratory Automation and Screening) conference on the future of lab automation. The post emphasizes that value comes not only from installing robots, but from building flexible, end‑to‑end integrated workflows.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, this approach is linked to Dash Bio achieving three‑day turnaround times for pre‑clinical work, in contrast with what it describes as manual processes still common in many labs. The company’s focus is portrayed as removing bottlenecks and accelerating drug development, with a specific mention of Olga Seltser’s role in leading the automation team.
For investors, the post suggests a strategic positioning around workflow integration and speed as competitive differentiators in pre‑clinical services. If Dash Bio can consistently deliver materially faster timelines, it could improve customer retention, pricing power, and revenue visibility, particularly from biotech and pharma clients under pressure to compress R&D cycles.
The post also implies ongoing investment in automation talent and infrastructure, which may carry near‑term cost implications but could scale efficiently as volume grows. Within the broader lab services and CRO landscape, an emphasis on modern automated workflows may help Dash Bio capture share from incumbents that rely on older manual approaches, potentially enhancing its long‑term growth profile.